A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Subject: Schizophrenia - PUBLISHED VIA Current Pharmaceutical Design
Author(s):
Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS
View Source >>
Related Studies:
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Published via Translational Psychiatry
Cannabidiol as a potential treatment for psychosis.
Published via European Neuropsychopharmacology
Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Published via Drug Testing and Analysis
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Published via Brazilian Journal of Medical and Biological Research
Peripheral endocannabinoid system dysregulation in first-episode psychosis.
Published via Neuropsychopharmacology